In vitro susceptibility of burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam

A Van Dalem, M Herpol, F Echahidi, C Peeters, I Wybo, E De Wachter, P Vandamme, D Piérard

Onderzoeksoutput: Article

17 Citaten (Scopus)

Samenvatting

We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole. Eighty-one and 63% of all BCC strains were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam, respectively. For temocillin, ceftazidime, piperacillin-tazobactam, and meropenem, at least 50% of the strains were susceptible. B. stabilis seems to be more resistant than other BCC species.

Originele taal-2English
Artikelnummere00590-18
Aantal pagina's18
TijdschriftAntimicrobial Agents and Chemotherapy
Volume62
Nummer van het tijdschrift9
DOI's
StatusPublished - sep 2018

Vingerafdruk

Duik in de onderzoeksthema's van 'In vitro susceptibility of burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam'. Samen vormen ze een unieke vingerafdruk.

Citeer dit